National burden of Ebola virus disease in Democratic Republic of the Congo: the urgency to act
Bilal Ahmad(University of Lahore), Aymar Akilimali(Roslin Institute), Elysée Byiringiro(University of Kigali), Martin Sagide(Jomo Kenyatta University of Agriculture and Technology), Priyadarshini Bhattacharjee, Marie Nkundakozera(University of Goma), Samson Hangi, Elie Kihanduka, Lucie Guruka(University of Goma), Christian Tague, Sylivia Ntamwinja(Kenya Methodist University), Michée Sanza Kanda(Ministry of Public Health), Amos Kipkorir Langat(African Centre for Technology Studies), Excellent Rugendabanga, Jones Onesime(Université libre des Pays des Grands Lacs)
Cited by 2
Related Papers
Revolutionary breakthrough: FDA approves CASGEVY, the first CRISPR/Cas9 gene therapy for sickle cell disease
|Annals of Medicine and Surgery|2024|87
Revolutionary breakthrough: FDA approves Vyjuvek, the first topical gene therapy for dystrophic epidermolysis bullosa
|Annals of Medicine and Surgery|2023|30
Self-medication and Anti-malarial Drug Resistance in the Democratic Republic of the Congo (DRC): A silent threat
|Tropical Medicine and Health|2022|29
Barriers Encountered Toward Pursuing a Neurosurgical Career: A Cross-Sectional Study Among Medical Students, Interns, and Junior Doctors in Africa
|World Neurosurgery|2022|26
Global, regional, and national burden of Chagas disease, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
|The Lancet Infectious Diseases|2025|25